E-cadherin expression was previously shown to be activated by RB and c-myc speci®cally in epithelial cells, through interaction with the AP-2 transcription factor. Here we show that only a wild type c-myc gene, coding for the two c-Myc proteins c-Myc2 and c-Myc1, was able to transactivate the E-cadherin promoter, in contrast to c-Myc2 or c-Myc1 alone which strongly repressed E-cadherin in both epithelial cells and ®broblasts. In addition, overexpression of c-myc2 or cmyc1 inhibited c-myc and RB-mediated activation in a dose-dependent manner, suggesting that the ratio of the two c-Myc proteins is essential for transactivation. We also showed by using several mutants of the E-cadherin promoter, that the AP-2 binding sites were the main target of c-myc2-and c-myc1-mediated repression. AP-2-mediated inhibition was cell-type speci®c, as was the activation. Nevertheless, when high amounts of c-myc2 and c-myc1 were used, a second c-myc-mediated repression was observed, possibly mediated by the Inr sequence of the E-cadherin promoter. However, this repression was independent of cell type. Our results suggest a new way to regulate c-myc transcriptional activity by interfering with the ratio of the two c-myc proteins, which has already been found to be disrupted in vivo in several tumor types.
Introduction
Altered c-myc expression is associated with neoplasia, particularly of B-cells, however the oncoprotein has also been found to be deregulated and overexpressed in a wide variety of carcinomas (Cole, 1986) . C-myc expression results in the activation and the repression of several genes involved in growth regulation and dierentiation (Henrickson and LuÈ scher, 1996) .
The c-myc gene encodes two major c-Myc proteins, c-Myc1(p67) and c-Myc2(p64), which dier in their amino-terminus and arise from alternative initiation at in-frame non-AUG and AUG codons (Hann et al., 1988) . The two translational forms of the Myc protein are expressed in all species of c-Myc examined so far (Hann and Eisenmann, 1984) , as well as for N-Myc (Ramsay et al., 1986) and L-Myc proteins (DosakaAkita et al., 1991) . The ratio of the two c-Myc proteins is disrupted in several tumor types, either due to rearrangement of the c-myc locus by chromosomal translocation, or speci®c point mutation resulting in the loss of c-Myc1 expression as in Burkitt's lymphoma cells or by increased c-Myc2 protein synthesis in other neoplastic cells (Hann and Eisenmann, 1984; Hann et al., 1988) . In normal growth conditions, the synthesis of the c-Myc proteins is dierentially regulated. CMyc2 is synthesized in growing cells, while synthesis of the non-AUG protein increases dramatically to levels equal to or greater than those of c-Myc2 as the cells approach high density (Hann et al., 1992) .
c-Myc proteins act as both positive and negative transcriptional regulators (Henrikson and LuÈ scher, 1996) . However, they require partners to bind to speci®c DNA sequences. Heterodimerization with Max protein allows binding to E-box Myc site (EMS) DNA sequences (Blackwell et al., 1990) . c-Myc binding capacity and transcriptional ability can also be modulated by other proteins interacting either with its C-terminal domain, such as YY-1 (Shrivastava et al., 1993) , TFII-I (Roy et al., 1993) and AP-2 (Gaubatz et al., 1995) , or with its N-terminal domain, as in the case of TBP (Maheswaran et al., 1994) . It has also been shown that only c-Myc1 strongly and speci®cally activates transcription of the C/EBP sequence within the EFII enhancer element of the Rous Sarcoma Virus long terminal repeat .
We recently reported that the c-myc proto-oncogene speci®cally activates transcription of the E-cadherin promoter in epithelial cells through the AP-2 transcription factor (BatscheÂ et al., 1998) . In this study, we explored a possible dierential eect of the two c-Myc proteins, c-Myc2 and c-Myc1, on Ecadherin transcription. We report that only a wild type c-myc expression vector expressing the two c-Myc proteins, c-Myc1 and c-Myc2, is able to transactivate the E-cadherin promoter in epithelial cells. The expression of each c-Myc protein alone not only failed to activate E-cadherin expression, but strongly repressed it. Moreover, the c-myc-mediated activation of E-cadherin was inhibited in a dose-dependent manner by overexpression of one or the other of the c-Myc proteins alone.
this construct is strongly activated by SV Hc-myc1-2-3 in a concentration-dependent manner (BatscheÂ et al., 1998 and Figure 1 ). SV Hc-myc1-2-3 is a human c-myc genomic clone derived from normal cells and containing all three exons and is therefore able to synthesize the two c-Myc proteins, c-Myc2 and c-Myc1 (Land et al., 1986 and Figure 2B ). When the ®rst exon was deleted of the genomic c-myc gene, resulting in the SV Hc-myc2-3 construct that synthesized only the c-Myc2 protein (Land et al., 1986 and Figure 2B ), E-cadherin activation was no longer observed and in contrast, this promoter was repressed up to ®vefold in a dosedependent manner (Figure 1) . Similarly, a point mutation on the murine c-myc cDNA under CMV promoter control selectively suppressing the translation of c-Myc1 and allowing exclusively that of c-Myc2 , abolished the transactivating eect of the E-cadherin promoter and induced a repression up to 25-fold, also in a dose-dependent manner (Figure 1) . These results suggest two possibilities. The ®rst is that the two c-Myc proteins are necessarily required for activation. The second is that c-Myc1 alone has the ability to stimulate and c-Myc2 to repress gene expression. To decide between these two alternatives, the 7178 E-cadherin reporter was cotransfected with a CMV c-myc1 vector expressing only the larger c-Myc1 protein and Figure 2B ). Similar repression of E-cadherin expression was also observed with this c-myc1 expression vector, arguing for the ®rst possibility (Figure 1 ). Ecadherin CAT was also cotransfected with increasing amounts of control vectors to exclude the possibility that the CAT activity was due to competition of transacting factor(s) with SV40 and CMV promoters (Figure 1) . Similar results were also obtained with human c-myc2 and c-myc1 cDNA under RSV promoter control, mut3 and mut15 (Blackwood et al., 1994) (data not shown). In addition experiments Figure 1 Dose-dependent repression of the murine E-cadherin promoter by c-Myc1 and c-Myc2 proteins in MDCK epithelial cells and in NIH3T3 ®broblasts, respectively. MDCK epithelial cells and NIH3T3 ®broblasts were transfected with 3 mg of 7178 Ecadherin CAT and with pUC DNA (baseline value) or with increasing amounts of SV Hc-myc1-2-3 (wild type), SV Hc-myc2-3, CMV c-myc2 and CMV c-myc1 expression vectors. Total DNA was always kept constant by adding pUC DNA. As controls, the 7178 E-cadherin CAT was cotransfected with expression plasmids without insert, pSV 2 D (SV control) or pRc/CMV (CMV control). The indicated values are averages expressed as fold activation or inhibition of CAT activity relative to the baseline value (equal to 1) obtained by cotransfecting the 7178 E-cadherin CAT promoter with pUC DNA. Each value is expressed after normalization for transfection eciency using pHbALacZ as an internal control. The results are from at least three experiments performed in duplicate and standard deviation bars are shown
Repression by c-Myc1 and c-Myc2 and activation by genomic c-myc E Batsche Â and C Cre Â misi were also reproduced in MCF7 human epithelial mammary cells (data not shown).
In order to demonstrate the functionality of the dierent c-myc constructs and to ®rmly establish the dierential eect of the wild type c-myc versus c-myc1 and c-myc2, we ®rst measured the activation of a CAT reporter construct containing four copies of the EMS sequence, (EMS) 4 CAT, previously shown to be modestly activated by c-myc (Kretzner et al., 1992) . All c-myc constructs, regardless of whether they expressed one or both c-Myc proteins, similarly transactivated the (EMS) 4 CAT reporter gene, in agreement with previous studies using the same experimental approach and the same reporter ( Figure  2A , Kretzner et al., 1992; Hann et al., 1994; Blackwood et al., 1994) . These results therefore demonstrate that the overexpressed c-Myc1 and c-Myc2 proteins are functionally active and capable of transactivation.
We then determined by Western blot the amount of c-Myc protein produced in each case. Figure 2B shows that c-Myc protein levels were similar between both the human constructs and the murine constructs, therefore excluding that the functional dierence was caused by quantitative eects and unambiguously demonstrating that each c-myc construct synthesizes the expected c-Myc protein(s). Both c-Myc1 and c-Myc2 are clearly produced by the wild type genomic c-myc construct, SV Hc-myc1-2-3. The ratio of endogenous c-Myc was also analysed in MDCK cells ( Figure 2C ). It is similar to the ratio produced by SV Hc-myc1-2-3, to other human cells like MCF7 mammary epithelial cells or keratinocyte Hacat cells, and to other previously analysed cells by Hann (1994) i.e. about 1 ± 10 or 1 ± 20 ( Figure 2C ). Furthermore, we checked that in our system, c-myc transfection did not induce apoptosis (data not shown).
We constantly observed a stronger inhibition with the mouse c-myc constructs CMV c-myc1 and CMV c-myc2 than with the human SV Hc-myc2-3. This dierence is probably due to the amount of c-Myc proteins produced in each case. Since it was not possible to test this possibility directly because we had to use dierent c-myc antibodies, we compared in a transient transfection assay the relative expression of the SV40 and CMV promoters. Indeed, the CMV promoter gave a much more ecient tenfold higher expression, than SV40 (data not shown).
All these results show that only a wild type c-myc gene expressing the two c-Myc proteins, c-Myc2 and cMyc1, was able to activate the E-cadherin promoter in canine and human epithelial cells, whereas c-myc2 and c-myc1 repressed it very strongly.
Inhibition of c-myc-mediated E-cadherin activation by overexpression of c-myc2 or c-myc1
If activation requires a strict ratio of the two c-Myc proteins, then the overexpression of one or the other c-Myc protein might disturb this equilibrium and result in inhibition of activation. This is in fact what we observed. When increasing amounts of SV Hcmyc2-3, CMV c-myc2 or CMV c-myc1 were added to the cotransfection of 7178 E-cadherin with SV Hcmyc1-2-3, a dose-dependent inhibition of E-cadherin promoter activation was observed which, for the Figure 3 Wild type c-myc-mediated activation of E-cadherin is inhibited by increasing amounts of c-Myc1 and c-Myc2 proteins. MDCK cells were cotransfected with 3 mg of 7178 E-cadherin CAT and 5 mg of SV Hc-myc1-2-3 and increasing amounts of SV Hc-myc2-3, CMV c-myc2, CMV c-myc1 expression vectors (in black). As a control, the 7178 E-cadherin CAT was cotransfected with 5 mg of SV Hc-myc1-2-3 and increasing amounts of pSV 2 D (SV control) or pRc/CMV (CMV control) (in gray) or pUC DNA (baseline value). Total DNA was always kept constant by adding pUC DNA. The values were determined as described in Figure 1 highest amounts of CMV c-myc2 and CMV c-myc1, was followed by repression of E-cadherin promoter expression (Figure 3 ). For each amount of SV Hcmyc2-3, CMV c-myc2 and CMV c-myc1 added, assays were also performed with SV and CMV control vectors. Figure 3 shows that these vectors did not aect transactivation of the E-cadherin promoter. Furthermore the ratio of endogenous c-Myc proteins in MDCK cells was found unchanged after transfection of exogenous c-myc ( Figure 2C ). Exogenous cMyc could not be detected by Western blot in MDCK cells. We attempted to transactivate the E-cadherin promoter by cotransfecting c-myc1 and c-myc2 expression vectors together at dierent ratios, without success (data not shown). One possible explanation is that the in vivo ratio of the two c-Myc proteins is very dynamic and in continuous evolution, following the growth state of the culture as shown by Hann et al. (1992) , a situation extremely dicult to reproduce by using two dierent c-myc constructs.
We previously reported that the retinoblastoma (RB) protein, like c-Myc, transactivates the Ecadherin promoter to the same extent in MDCK epithelial cells by interacting with the AP-2 factor (BatscheÂ et al., 1998 and Figure 4) . Cotransfection of both RB and c-myc did not result in increased transactivation, suggesting that the two nuclear regulators act together on the same target (BatscheÂ et al., 1998) . We therefore tested whether c-myc2 and c-myc1 could interfere with RB-mediated activation of the E-cadherin promoter. Interestingly, cotransfection of RB with c-myc2 or c-myc1 inhibited RB-mediated activation in a dose-dependent manner and resulted in E-cadherin repression, con®rming that RB and c-myc functionally interact to activate E-cadherin expression (Figure 4 ) and that c-myc2 and c-myc1 displayed their inhibitory activity even in this context.
c-myc2 and c-myc1-mediated repression also occurs in 3T3 ®broblasts
Since c-myc-mediated E-cadherin activation does not occur in ®broblasts (BatscheÂ et al., 1998 and Figure 1) , we wanted to see if the same was true for c-myc2 and c-myc1-mediated E-cadherin repression. This was done by testing the eects of the c-myc2 and c-myc1 vectors in these cells. Interestingly, we observed that the three c-myc2 and c-myc1 vectors repressed E-cadherin expression to the same extent in ®broblasts as in MDCK epithelial cells (Figure 1 ), suggesting that even in cells where c-myc is not able to act positively, there is a functional dierence between wild type c-myc (SV Hc-myc1-2-3) and mutant c-myc expressing only c-Myc2 or c-Myc1.
c-myc repression in epithelial cells is mediated by AP-2
The E-cadherin promoter requires the binding of the AP-2 transcription factor to three elements (the palindromic E-pal element and the GC1 and GC2 boxes) in order to be functional (Behrens et al., 1991; Hennig et al., 1996) . Using a series of deletions and point mutations, we showed that each of these elements was similarly targeted by c-myc activation (BatscheÂ et al., 1998) . The question now was to determine if the same sequences would also be the target for c-myc2 and c-myc1 repression. We performed cotransfection assays using the same deletions and point mutations of the E-cadherin promoter as in a previous study (BatscheÂ et al., 1998) . Figure 5A clearly shows that the E-cadherin constructs still containing AP-2 binding sites (7178, 758 E-cadherin and E-Pal) were similarly activated by SV Hc-myc1-2-3 and repressed by SV Hc-myc2-3. In contrast, when the AP-2 binding sites were inactivated (two sites for mut-P-GC1 and all of them for mut*) or deleted as for 721 E-cadherin, repression by SV Hc-myc2-3 was lost, as was activation by SV Hc-myc1-2-3 ( Figure 5A and BatscheÂ et al., 1998) . This experiment demonstrates that the same AP-2 binding sites were targeted by wild type c-myc to activate and by c-myc2 to repress the E-cadherin promoter.
We next tested the eects of CMV c-myc2 and CMV c-myc1. When the AP-2 binding sites were inactivated, the levels of repression were again greatly reduced but not totally inhibited ( Figure 5B ). Since we found that the CMV promoter is about tenfold stronger than the SV promoter, we reproduced these experiments with decreasing amounts of CMV c-myc2 and c-myc1. Interestingly, low amounts of these CMV c-myc vectors (0.125 and 0.250 mg) induced levels of repression similar to that obtained with SV Hc-myc2-3, i.e. an absence of repression when the AP-2 binding Figure 4 RB-mediated activation of the E-cadherin promoter is inhibited by c-myc2 and c-myc1 but not by wild type c-myc. MDCK cells were cotransfected with 3 mg of 7178 E-cadherin CAT and with pUC DNA (baseline value) or with 5 mg of RB expression vector and increasing amounts of SV Hc-myc2-3 or CMV c-myc2, CMV c-myc1 expression vectors (in black). As controls, the 7178 E-cadherin CAT was cotransfected with RB and 5 mg of wild type c-myc (SV Hc-myc1-2-3) and either pSV 2 D (SV control) or pRc/CMV (CMV control) (in gray). Total DNA was always kept constant by adding pUC DNA. The values are determined as described in Figure 1 sites were inactivated ( Figure 5C , mut*). For higher amounts, we again observed less inhibition for mut* (about 2 ± 3-fold) than for the wild type promoter 7178 (about 12-fold). These results indicate that two kinds of repression exist in MDCK cells, one of which is dependent on the AP-2 binding sites and the other not, since it is observed with mut* and 721 Ecadherin devoid of AP-2 binding sites. This second type of repression was unmasked only when high amounts of c-Myc proteins were used. The 721 Ecadherin promoter does not have a TATA box but does possess an Inr sequence, CTCA(+1)CTGG (Behrens et al., 1991) . Since it was previously shown that c-myc2 repressed two dierentiation-speci®c genes, the C/EBPa and serum albumin genes through the Inr sequence (Li et al., 1994) , we postulate that in Figure 5 Determination of the responsive elements of c-Myc2 and c-Myc1-mediated inhibition of the E-cadherin promoter. The reporters used in this study are depicted at the top. (A) AP-2 binding sites mediate the SV Hc-myc2-3 inhibition of the E-cadherin promoter. MDCK cells were cotransfected with 3 mg of 7178, 758, 721, mut-P-GC1, mut* E-cadherin CAT and (E-Pal) 4 SV and with 5 mg of pUC DNA (baseline value), SV Hc-myc2-3 or pSV 2 D (SV control). Controls for E-cadherin activation by c-myc were performed by using SV Hc-myc1-2-3 as previously reported (BatscheÂ et al., 1998) . (B) CMV c-myc2 and CMV c-myc1-mediated inhibition was partly due to AP-2 binding sites. The same E-cadherin CAT constructs as described in (A) (3 mg of each) were cotransfected in MDCK cells with 2 mg of pUC DNA (baseline value), CMV c-myc2, CMV c-myc1 or pRc/CMV (CMV control). (C) Two inhibition sites respond to dierent amounts of c-myc2 and c-myc1. MDCK cells were cotransfected with 3 mg of either 7178 or mut* E-cadherin CAT and with increasing amounts of pUC DNA (baseline value), or with CMV c-myc2, CMV c-myc1 or pRc/CMV (CMV control; not shown). Total DNA was always kept constant by adding pUC DNA. In mut-P-GC1 two of the three AP-2 binding sites were mutated and functionally inactivated. In mut* the three AP-2 binding sites and the CAAT box were mutated, leaving only the Inr sequence intact. All indicated values, determined as in Figure 1 , are averages expressed as fold activation or inhibition of CAT activity relative to the baseline value obtained by cotransfecting each E-cadherin CAT construct with pUC DNA the case of the E-cadherin promoter, c-myc2 is also repressing through the Inr sequence.
To con®rm the involvement of AP-2 in c-mycmediated repression, we tested whether AP-2 activity was directly inhibited by c-myc2 or c-myc1. We performed cotransfection assays with an AP-2 expression vector, pPADH-AP-2 in human HepG2 and C33A cells devoid of endogenous AP-2 activity (Imagawa et al., 1987 and data not shown). The Table 1 shows that AP-2 activity was totally inhibited by c-myc2 and cmyc1 in both HepG2 and C33A cells. Thus, in contrast to wild type c-myc which acts as an activator of AP-2 (BatscheÂ et al., 1998), c-myc2 and c-myc1 behave as inhibitors of AP-2.
We previously showed that c-Myc AP-2-mediated transcription is not restricted to the E-cadherin promoter, but is also observed with the HTLV-1 LTR (BatscheÂ et al., 1998) , also known to be stimulated by AP-2 (Muchardt et al., 1992) . We determined whether c-myc2-and c-myc1-mediated repression also occurred on this promoter as well as on a chimera construct containing three AP-2 binding sites (AP-2 CAT). Figure 6 shows that the two promoters were repressed by SV Hc-myc2-3, CMV cmyc2 and CMV c-myc1.
As mentioned, the C/EBPa and serum albumin genes were found to be repressed by c-myc2 (Li et al., 1994) . Since only a c-myc2 expressing construct was used in this study, we sought to determine whether a wild type c-myc, coding for the two c-Myc proteins, in contrast to c-myc2, would transactivate these promoters. In agreement with our above mentioned results, the C/EBPa and serum albumin promoters were both strongly activated by wild type c-myc ( Figure 6 ). It is noteworthy that the AP-2 factor was recently shown to be involved in C/EBPa expression (Jiang et al., 1998) .
Thus in MDCK cells the E-cadherin promoter is subjected to two kinds of repression by c-myc2 and cmyc1, one dependent on functional AP-2 binding sites and observed with low amounts of c-Myc2 and c-Myc1 proteins, and the other perceptible only with high Controls with only the conab2 promoter were also performed (not shown). All values of each construct were determined as in Figure 1 Repression by c-Myc1 and c-Myc2 and activation by genomic c-myc E Batsche Â and C Cre Â misi amounts of c-Myc2 and c-Myc1 proteins and may be mediated by the Inr.
c-myc-mediated repression in mesenchyme cells is independent of AP-2
Having identi®ed two types of c-myc2-and c-myc1-mediated repression with dierent molecular mechanisms in MDCK epithelial cells, we next explored whether this also occurred in 3T3 ®broblast cells. We compared the levels of repression of the wild type and mut* E-cadherin promoter in the two cell types and observed that even in the absence of functional AP-2 binding sites, the E-cadherin mut* promoter was repressed in ®broblasts by CMV c-myc2 and CMV cmyc1 as well as by SV Hc-myc2-3 (Table 2 ). These results indicate that in 3T3 cells, E-cadherin promoter repression is independent of AP-2 and occurs with lower amounts of c-myc than in epithelial cells, since SV Hc-myc2-3 repressed mut* (Table 2 ). This study, together with our previous work, shows that in both epithelial and ®broblast cells, wild type c-myc and cmyc2 and c-myc1 have dierent eects on E-cadherin promoter expression. All these results demonstrate that the AP-2 binding sites in the E-cadherin promoter are the main target for c-myc2 and c-myc1-mediated repression and for wild type c-myc-mediated activation in epithelial cells.
Discussion
Our results demonstrate that only a wild type c-myc, simultaneously expressing the two c-Myc proteins cMyc proteins c-Myc2 and c-Myc1, can activate the Ecadherin promoter in epithelial cells. In contrast, the deleted-exon1 or mutated c-myc vectors expressing only one of the other c-Myc protein, not only lost this activating property, but became strong repressors of Ecadherin expression. These results imply that both cMyc proteins are required to positively regulate the Ecadherin promoter, as previously suggested for the Endo A gene coding for a cytokeratin (Onclercq et al., 1989) , and that the ratio between the two c-Myc proteins, which is regulated at the translational level, is presumably very important since activation by wild type c-myc is inhibited in a dose-dependent manner by overexpression of one or other of the c-Myc proteins alone. Cell density, Max levels, cell type and cell state (undierentiated, dierentiated or tumoral) might be important criteria for determining this ratio. In this regard, Max was found to repress c-myc-mediated activation of E-cadherin (data not shown) and its protein levels strongly decreased at high cell density (Martel et al., 1995) . In addition, the ratio of c-Myc2 to c-Myc1 was dierent between tumor cells and normal cells (Hann et al., 1984) and in quiescent cells versus proliferating cells (Hann et al., 1992) .
Activation of E-cadherin by wild type c-myc was shown to be cell type speci®c and to occur speci®cally in epithelial cells (BatscheÂ et al., 1998) . Interestingly, cmyc2 and c-myc1 repressed the E-cadherin promoter in both canine and human epithelial cells and ®broblasts. These results demonstrate that even in cell types where wild type c-myc cannot act positively, there is an important functional dierence between wild type cmyc and c-myc2 and c-myc1. However, the molecular mechanism underlying repression in both cell types showed important dierences. In MDCK epithelial cells, two molecular mechanisms of repression were found. Very interestingly, AP-2 binding sites were shown to be the target of both activation and repression, depending on the dierent forms of c-Myc proteins. These results demonstrate a new mechanism of regulation of c-myc function which might be dependent on the ratio of the two c-Myc proteins, and furthermore they are consistent with the abovementioned data concerning the variations in the cMyc2 to c-Myc1 ratio observed in several physiological conditions, particularly tumorigenesis (Hann et al., 1984) . This AP-2-dependent mechanism occurred exclusively in epithelial cells, i.e., in cells expressing E-cadherin and high amounts of AP-2, and was not observed in ®broblasts, where E-cadherin is not expressed.
In addition to this mechanism, another mode of repression was observed in both ®broblasts and MDCK epithelial cells, but only with higher amounts of c-Myc proteins. This mechanism is independent of AP-2 and might be mediated via the Inr sequence, since it was observed with the short version of the Ecadherin promoter, the 21 bp promoter devoid of a TATA box but harboring an Inr sequence (Behrens et al., 1991) . It is noteworthy that the mechanism concerning a general function such as the initiation of transcription is not cell type speci®c, whereas the other mechanism concerning the cell-type expression of E-cadherin, since the AP-2 transcription factor is concerned, is cell type speci®c.
Several cellular genes involved in cell adhesion, such as integrin and MHC (Bernards et al., 1986; Inghirami et al., 1990; Versteeg et al., 1988) , and in differentiation, such as collagen genes (Yang et al., 1991) , C/ EBPa and albumin promoters (Li et al., 1994) are subject to c-myc negative control. It is noteworthy that in all cases a unique truncated p64 c-Myc protein (cMyc2) was used. It would be very interesting to test whether a wild type c-myc gene would produce an opposite eect. In agreement with this prediction, we showed that the C/EBPa and albumin promoters were MDCK epithelial cells and NIH3T3 ®broblasts were cotransfected with 3 mg of either 7178 or mut* E-cadherin CAT and with each of the following c-myc expression vectors: 5 mg of SV Hc-myc2-3, 2 mg of CMV c-myc2 and 2 mg of CMV c-myc1. As controls, the reporter constructs were cotransfected with either 5 mg of pSV2D (SV control) or 2 mg of pRc/CMV (CMV control). The values are averages expressed as fold inhibition of CAT activities relative to the baseline obtained by cotransfecting each E-cadherin CAT construct with 5 or 2 mg of pUC DNA in each cell type
Repression by c-Myc1 and c-Myc2 and activation by genomic c-myc E Batsche Â and C Cre Â misi activated only by a wild type c-myc vector expressing the two c-Myc proteins, in contrast to c-myc2 which repressed them ( Figure 6 and Li et al., 1994) . Similar results were also reported for the cytokeratin murine endoA and endoB and early adenovirus E4 promoters (Onclercq et al., 1988 (Onclercq et al., , 1989 .
The mechanism by which a change in the ratio of c-Myc1/c-Myc2 switches E-cadherin expression from positive to negative regulation is still unclear. We showed that activation of E-cadherin by wild type cmyc is mediated by AP-2 (BatscheÂ et al., 1998), which is a Helix ± span ± Helix protein (Williams and Tjian, 1991) , and that wild type c-myc acts as an activator of AP-2 in MDCK epithelial cells, whereas that c-myc1 and c-myc2 act as inhibitors of AP-2. Furthermore, c-Myc and AP-2 were shown to form intracellular complexes in vivo (Gaubatz et al., 1995) . The c-Myc/AP-2 complex, as we know from c-Myc interacting proteins (Henrikson and LuÈ scher, 1996) and from the complexity of the transcriptional machinery, presumably represents a small part of a much larger complex involving many other transcription factors, cofactors and nuclear regulators. It might be hypothesized that the asymmetrical Ntermini of c-Myc1 and c-Myc2 ensure the right contact with other factors necessary for E-cadherin transcription and perhaps for activation of other genes as well. A subtle change in the ratio between the two c-Myc proteins might cause dramatic changes, resulting in loss of an essential factor and repression. Our results supporting an important role of the c-myc-protein ratio are consistent with the above-mentioned studies demonstrating that the ratio of the c-Myc proteins diers in tumor cells as compared to normal cells .
Several other regulatory proteins, including protooncogenes, transcription factors (krox 24, RAR-b3), kinases and receptor kinase (pim-1, hck-1, Itk) and growth factors (bFGF), also initiate translation at a non-AUG codon (see Hann, 1994 for review). In some cases it has been shown that the two dierent translated forms have distinct biological functions (Hann, 1994) . This would suggest that the two translational forms of c-Myc are also probably not fortuitous and should both be taken into account in studies of c-myc function.
Our results imply that any experimental approach involving overexpression of c-myc2, which was the case in most studies on c-myc or c-myc1, leads to deregulation of endogenous c-myc functions, since the c-Myc protein ratio is disrupted. The eects observed in these cases are not a re¯ection of c-myc function, but in contrast re¯ect the loss of its function. In agreement with this assumption, it was shown that overexpressed c-myc1 or c-myc2 were independently able to collaborate with bcr ± abl in the transformation of ®broblasts (Blackwood et al., 1994) .
The overall positive or negative eect of c-myc on speci®c gene expression would be cell type speci®c. cmyc would repress or activate the same gene depending on whether the cell is dierentiated, undierentiated or tumoral (see also CreÂ misi, 1989) . The ratio of the two c-Myc proteins might be dierent in these dierent situations. This hypothesis might constitute a paradigm for c-myc transcriptional activity.
Materials and methods

Cell culture and transfection
MDCK, MCF7 and HaCat cell lines were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 5% fetal calf serum; NIH3T3, HepG2 and C33A cell lines were grown in 10% serum. Transfection assays were performed as previously described (BatscheÂ et al., 1998) . The amount of transfected DNA was kept constant by adding pUC18 plasmid DNA. As internal control, 1 mg of the bactbgal construct (pHbALacZ) was cotransfected with the other plasmids in each sample. CAT activity was calculated as the percentage of chloramphenicol converted into acetylated forms. The basal level of the reporter plasmid without cotransfection of an expression plasmid was set at unity. Each transfection was performed in duplicate and was reproduced at least three times with dierent plasmid preparations; the histograms shown in the ®gures are representative of these experiments. Each cotransfection experiment was also independently performed with plasmid controls containing only the promoter region of the expression plasmid pSV 2 D (SV control) and pRc/CMV (CMV control) promoters. When necessary, the ®nal CAT activity was corrected, depending on these controls.
Plasmid constructs
The E-cadherin promoter-CAT constructs (7178, 758, 721) , (E-Pal) 4 SV CAT, as well as constructs having point mutations in E-pal, CCAAT box, GC1 and GC2 boxes were previously described (Hennig et al., 1996) . The human genomic SV Hc-myc1-2-3 and SV Hc-myc2-3 (Land et al., 1986) , the human RB (SV RB) (Templeton et al., 1991) , the human cDNA AP-2 under alcohol dehydrogenase promoter control (pPADH-AP-2) (Williams et al., 1988) , (EMS) 4 CAT (Kretzner et al., 1992) , the C/EPBa promoter (7387/+3) (Li et al., 1994) and the rat albumin promoter (7191/+4) (Tronche et al., 1989) were also described. CMV c-myc1 and CMV c-myc2 were a kind gift of S Hann and are murine c-myc cDNA under CMV promoter control expressing exclusively c-Myc1 and c-Myc2 . Mut15 and mut3 were a kind gift of E Blackwood and B Eisenman and are human c-myc cDNA under RSV promoter control expressing exclusively c-Myc1 and c-Myc2 (Blackwood et al., 1994) .
Cells lysates and Western blot
Western blots and SDS whole cell extracts were performed as described (BatscheÂ et al., 1998) . The monoclonal 9E10 antibody purchased from Oncogene Science was used for detecting the human and canine c-Myc proteins and the rabbit polyclonal 06-213 (Spotts and Hann, 1990) for the mouse c-Myc proteins.
